Immune-Mediated Coagulopathy in COVID-19 Infection

Viral infections, such as Epstein–Barr virus, Coxsackieviruses, and cytomegalovirus, are frequently blamed as a trigger for immune-mediated inflammation and autoimmunity, including the development of antiphospholipid syndrome. A variety of underlying mechanisms have been suggested, including virus direct overstimulatory effect on both innate and adaptive immune responses, cross-reactivity with self-antigens, and, lastly, direct effect on regulatory functions.[1] However, the high infectivity and damaging effect of coronavirus disease 2019 (COVID-19) on the respiratory tract, endothelial cells, and both innate and adaptive immunity are far beyond those of the vast majority of other viruses. While most patients with COVID-19 infection experience only mild fever, cough, myalgia, and weakness, within a few days some develop bilateral interstitial pneumonia and later acute respiratory distress syndrome, with many of them requiring long-lasting mechanical ventilation and intensive care.[2] The severity of respiratory failure and mortality in COVID-19-infected patients was reported to correlate with higher infectious dose followed by active and prolonged viral replication in pneumocytes, macrophages, and other immune cells. COVID-19 infection is characterized by a high incidence of thrombotic coagulopathies, up to the development of disseminated intravascular damage in some critical cases.[3] [4] However, the link between enhanced immune responses, endothelial damage, and coagulopathy in COVID-19-infected patients is yet to be clearly defined.

Publikationsverlauf

Artikel online veröffentlicht:
02. September 2020

• References

• 1 Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev 2019; 18 (03) 306-311
• 2 Henderson LA, Canna SW, Schulert GS. et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol 2020; (e-pub ahead of print) DOI: 10.1002/art.41285.
• 3 Llitjos JF, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; (e-pub ahead of print) DOI: 10.1111/jth.14869.
• 4 Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res 2020; 30 (05) 367-369
• 5 Chen G, Wu D, Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130 (05) 2620-2629
• 6 Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020; 80 (06) 607-613
• 7 Li X, Xu S, Yu M. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; (e-pub ahead of print) DOI: 10.1016/j.jaci.2020.04.006.
• 8 Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46 (04) 586-590
• 9 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395 (10234): 1417-1418
• 10 Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020; 217 (06) e20200678
• 11 Wang F, Hou H, Luo Y. et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 2020; 5 (10) 137799
• 12 Zheng M, Gao Y, Wang G. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; 17 (05) 533-535
• 13 Xu H, Zhong L, Deng J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020; 12 (01) 8
• 14 Qin C, Zhou L, Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; (e-pub ahead of print) DOI: 10.1093/cid/ciaa248.
• 15 Thachil J, Tang N, Gando S. et al. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost 2020; (e-pub ahead of print) DOI: 10.1111/jth.14866.
• 16 Hossri S, Shadi M, Hamarsha Z, Schneider R, El-Sayegh D. Clinically significant anticardiolipin antibodies associated with COVID-19. J Crit Care 2020; 59: 32-34
• 17 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
• 18 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020; 382 (17) e38
• 19 Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020; (e-pub ahead of print) DOI: 10.1111/jth.14867.
• 20 Terpos E, Ntanasis-Stathopoulos I, Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95 (07) 834-847
• 21 Liu Y, Sun W, Guo Y. et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets 2020; 31 (04) 490-496